02601 Overview

Market Performance: After the Lunar New Year holiday, Chinese H-listed insurers have underperformed, with concerns about short-term profit risks and a lack of disclosed premium income data.

JPMorgan's Analysis: JPMorgan's report indicates that major insurers like PING AN and CHINA LIFE are rated as Overweight, with target prices set at $100 and $40, respectively, due to their recovery in life insurance sales.

Profit Forecasts: JPMorgan forecasts significant growth in FY2025 net profits for CHINA LIFE (47%), PING AN (19%), and CPIC (10%) year-over-year.

Short Selling Activity: There is notable short selling activity in both PING AN and CHINA LIFE, with respective ratios of 28.711% and 16.336%, reflecting market skepticism despite their growth prospects.

Stock Performance: Several insurance stocks in Hong Kong showed positive movements, with CHINA LIFE increasing by 1.935% and PICC GROUP by 2.744%.

Investment Ratings: Most stocks received a "Buy" rating, including CHINA LIFE, CPIC, and PICC GROUP, while CHINA TAIPING and NCI were rated as "Neutral".

Short Selling Data: Short selling activity varied, with PING AN having the highest short selling amount at $177.33M and a ratio of 22.445%.

Target Price Adjustments: Analysts have adjusted target prices for several stocks, with CHINA LIFE's target raised to HKD40 and PICC P&C's lowered to HKD20.5.

Earnings Announcement Period: The earnings announcement period for Hong Kong/China insurers for FY2025 will start on March 19, led by AIA, PRU, and ZA ONLINE.

Growth Expectations: Citi Research anticipates strong growth in new business value for Chinese life insurers, with China Life, Ping An, and CPIC expected to lead with growth rates of 38%, 32%, and 28%, respectively.

Earnings Forecast: The broker predicts solid earnings growth for FY2025, with significant increases expected for China Taiping, China Life, and NCI, among others.

Short Selling Data: The report includes short selling data for various insurers, indicating varying levels of short selling activity and ratios across different companies.

Citi's Negative Catalyst Watch on CPIC: Citi has initiated a 90-day negative catalyst watch on CPIC (02601.HK), predicting that its FY25 results will underperform compared to peers, with a projected 28% growth in new life insurance business.

Comparative Performance Expectations: The anticipated combined operating ratio for CPIC in FY25 is 98.0%, which is less favorable than major competitors like PICC GROUP and PING AN, whose ratios are forecasted at 97.3% and 97.1%, respectively.

Earnings Growth Projections: CPIC's projected 16% year-over-year earnings increase for FY25 is significantly lower than the expected growth rates of its competitors, such as CHINA TAIPING at 220% and CHINA LIFE at 47%.

Citi's Rating and Target Price: Despite the negative outlook, Citi has rated CPIC as a Buy and set a target price of HKD 44.9.

H Shares Performance: China Life and Ping An saw increases in share prices, while CPIC and NCI experienced slight declines; short selling ratios indicate varying investor sentiment across these companies.

A Shares Performance: China Life and Ping An of China had mixed results, with Ping An's rating upgraded from Hold to Buy, while NCI maintained a Hold rating despite a price increase.

Investment Ratings: Analysts have assigned ratings of Hold, Buy, and Underweight to various insurance companies, reflecting differing outlooks on their future performance.

Market Insights: CICC anticipates a new era in China's commercial health insurance sector, emphasizing four key areas for development.

Stock Performance: Several insurance companies, including PING AN and CHINA LIFE, showed positive stock performance with increases of 2.423% and 5.345%, respectively.

Short Selling Data: The short selling ratios for these companies varied, with CPIC having the highest ratio at 28.360%, while NCI had the lowest at 5.968%.

Analyst Ratings: All listed companies received an "Outperform" rating, indicating positive expectations from analysts.

Market Outlook: Citi has raised target prices for life insurers, favoring leaders like CHINA LIFE and PING AN, and anticipates a prosperous year for the Chinese life insurance sector.